GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (OTCPK:INCPF) » Definitions » 3-Year FCF Growth Rate

InnoCare Pharma (InnoCare Pharma) 3-Year FCF Growth Rate : -5.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma 3-Year FCF Growth Rate?

InnoCare Pharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -5.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -50.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of InnoCare Pharma was 51.00% per year. The lowest was -121.10% per year. And the median was -38.65% per year.


Competitive Comparison of InnoCare Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, InnoCare Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's 3-Year FCF Growth Rate falls into.



InnoCare Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


InnoCare Pharma  (OTCPK:INCPF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


InnoCare Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (InnoCare Pharma) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.